|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Brian Lian||Pres, CEO & Director||752k||N/D||1966|
|Mr. Michael Morneau||VP of Fin. & Admin.||375,33k||N/D||1965|
|Mr. Gregory S. Zante||VP of Fin. & Operations||N/D||N/D||1971|
|Ms. Amy Broidrick||Sr. VP of Corp. Devel.||N/D||N/D||N/D|
|Ms. Marianne Mancini||Sr. VP of Clinical Operations||N/D||N/D||N/D|
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in preclinical stage for X-linked adrenoleukodystrophy. The company was founded in 2012 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Viking Therapeutics, Inc. al 29 luglio 2019 è 9. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 8.